Tansel Çakır
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tansel Çakır has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jamshid Hamdard
Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey
2 shared publications - Omer Fatih Olmez
Faculty of Medicine, Medical Oncology Department, Medipol University, İstanbul, Türkiye, Turkey (Türkiye)
2 shared publications - Tamer Atasever
Department of Nuclear Medicine, İstanbul Medipol University Faculty of Medicine, İstanbul, Türkiye
2 shared publications - Özgür Açıkgöz
Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey
2 shared publications Ahmet Bilici
Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, Istanbul, Turkey
1 shared publication- Ahmet Bilici
Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 50, 1-8
Real-World Outcomes of 177Lu-PSMA-617 Radioligand Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer
Objective: Among recently developed treatment strategies for advanced prostate cancer, 177Lu-PSMA-617–based radioligand therapy has shown considerable clinical potential in patients with metastatic castration-resistant disease. However, predictors of treatment response and survival outcomes remain incompletely defined. Methods: This retrospective analysis included 38 patients who received up to 6 cycles of 177Lu‑PSMA‑617 (4.0-6.8 GBq/cycle; mean 5.5 GBq) administered every 6-9 weeks. Clinical variables, laboratory findings, and prostate-specific membrane antigen–positron emission tomography/computed tomography metrics, including prostate-specific antigen (PSA), alkaline phosphatase (ALP), and maximum standardized uptake value (SUVmax), were evaluated for their association with treatment response, progression‑free survival (PFS), and overall survival (OS). Results: At the time of analysis, the median follow-up duration was 12.2 months (range: 1.1-65.8 months). Median PFS was 5.8 months, whereas median OS reached 12.3 months. Objective response to therapy was observed in 36.8% of the study population. Adverse events were common, occurring in 86.8% of patients overall, with grade 3-4 toxicities recorded in 57.9% of cases. Posttherapy SUVmax below 4 independently predicted prolonged PFS, whereas Eastern Cooperative Oncology Group (ECOG) performance status, ALP, PSA, and post‑treatment SUVmax independently influenced OS. Conclusion: 177Lu-PSMA-617 demonstrated meaningful clinical activity in this heavily pretreated cohort. However, the relatively high frequency of severe treatment-related toxicities highlights the importance of careful patient selection and close clinical monitoring. Functional imaging findings (post-treatment SUVmax), together with ECOG performance status and biochemical markers, may improve prognostic stratification in patients receiving this therapy. Cite this article as: Karcı E, Atasever T,Ç.akır T, et al. Real-world outcomes of lu-PSMA-617 radioligand therapy in elderly patients with metastatic castration-resistant prostate cancer. Cerrahpaşa Med J. 2026, 50, 0082, doi: 10.5152/cjm.2026.26082.
- 22 October 2026
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 50, 1-8
Open AccessReal-World Outcomes of 177Lu-PSMA-617 Radioligand Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer
Objective: Among recently developed treatment strategies for advanced prostate cancer, 177Lu-PSMA-617–based radioligand therapy has shown considerable clinical potential in patients with metastatic castration-resistant disease. However, predictors of treatment response and survival outcomes remain incompletely defined. Methods: This retrospective analysis included 38 patients who received up to 6 cycles of 177Lu‑PSMA‑617 (4.0-6.8 GBq/cycle; mean 5.5 GBq) administered every 6-9 weeks. Clinical variables, laboratory findings, and prostate-specific membrane antigen–positron emission tomography/computed tomography metrics, including prostate-specific antigen (PSA), alkaline phosphatase (ALP), and maximum standardized uptake value (SUVmax), were evaluated for their association with treatment response, progression‑free survival (PFS), and overall survival (OS). Results: At the time of analysis, the median follow-up duration was 12.2 months (range: 1.1-65.8 months). Median PFS was 5.8 months, whereas median OS reached 12.3 months. Objective response to therapy was observed in 36.8% of the study population. Adverse events were common, occurring in 86.8% of patients overall, with grade 3-4 toxicities recorded in 57.9% of cases. Posttherapy SUVmax below 4 independently predicted prolonged PFS, whereas Eastern Cooperative Oncology Group (ECOG) performance status, ALP, PSA, and post‑treatment SUVmax independently influenced OS. Conclusion: 177Lu-PSMA-617 demonstrated meaningful clinical activity in this heavily pretreated cohort. However, the relatively high frequency of severe treatment-related toxicities highlights the importance of careful patient selection and close clinical monitoring. Functional imaging findings (post-treatment SUVmax), together with ECOG performance status and biochemical markers, may improve prognostic stratification in patients receiving this therapy. Cite this article as: Karcı E, Atasever T,Ç.akır T, et al. Real-world outcomes of lu-PSMA-617 radioligand therapy in elderly patients with metastatic castration-resistant prostate cancer. Cerrahpaşa Med J. 2026, 50, 0082, doi: 10.5152/cjm.2026.26082.
- Open Access
- 25 September 2026
- Published by Taylor & Francis in OncoImmunology
- Vol. 15 (1)
Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer
1. Despite the addition of immune checkpoint inhibitors (ICIs) to platinum-etoposide as first-line therapy, extensive-stage small cell lung cancer (ES-SCLC) remains a highly lethal disease, with a ...
- 25 September 2026
- Published by Taylor & Francis in OncoImmunology
- Vol. 15 (1)
Open AccessCircadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer
1. Despite the addition of immune checkpoint inhibitors (ICIs) to platinum-etoposide as first-line therapy, extensive-stage small cell lung cancer (ES-SCLC) remains a highly lethal disease, with a ...
- Open Access
- 8 January 2026
- Published by Acibadem Universitesi Saglik Bilimleri Dergisi in Acibadem Universitesi Saglik Bilimleri Dergisi
- Vol. 17 (January, F)
Global Public Interest in Prostate Cancer Imaging: A Google Trends Analysis of PSMA PET and Conventional Modalities (2010–2025)
Purpose: This study evaluates and compares global public interest in Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) imaging with traditional prostate cancer imaging modalities using Google Trends data from 2010 to 2025, and analyzes how digital engagement aligns with key clinical milestones.Methods: This observational infodemiology study analyzed Google Trends data for four search terms: 'PSMA PET Scan', 'MRI Prostate Cancer', 'Bone Scan Prostate Cancer', and 'Prostate Cancer Scan' from January 2010 to April 2025. Average interest scores were calculated for pre- and post-milestone periods. Linear regression estimated PSMA PET growth rates post-2020, and milestone-aligned surge analysis quantified changes surrounding key clinical events including the proPSMA trial publication, FDA approval, and guideline updates.Results: PSMA PET search interest increased dramatically after March 2020, with sustained monthly growth (R²=0.87). By 2023, PSMA PET interest surpassed bone scan levels and approached MRI interest. FDA approval of Gallium-68 PSMA-11 generated the strongest public response, while guideline updates showed minimal immediate impact. Overall average interest rankings were: Prostate Cancer Scan (44.9), MRI Prostate Cancer (40.8), PSMA PET Scan (20.6), and Bone Scan Prostate Cancer (13.7).Conclusion: PSMA PET has rapidly captured public interest parallel to its clinical validation and regulatory approval, reflecting growing importance in prostate cancer imaging. Infodemiology approaches provide valuable insights into medical innovation ad3option and assist stakeholders in anticipating trends and developing health policies in molecular imaging.
- 8 January 2026
- Published by Acibadem Universitesi Saglik Bilimleri Dergisi in Acibadem Universitesi Saglik Bilimleri Dergisi
- Vol. 17 (January, F)
Open AccessGlobal Public Interest in Prostate Cancer Imaging: A Google Trends Analysis of PSMA PET and Conventional Modalities (2010–2025)
Purpose: This study evaluates and compares global public interest in Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) imaging with traditional prostate cancer imaging modalities using Google Trends data from 2010 to 2025, and analyzes how digital engagement aligns with key clinical milestones.Methods: This observational infodemiology study analyzed Google Trends data for four search terms: 'PSMA PET Scan', 'MRI Prostate Cancer', 'Bone Scan Prostate Cancer', and 'Prostate Cancer Scan' from January 2010 to April 2025. Average interest scores were calculated for pre- and post-milestone periods. Linear regression estimated PSMA PET growth rates post-2020, and milestone-aligned surge analysis quantified changes surrounding key clinical events including the proPSMA trial publication, FDA approval, and guideline updates.Results: PSMA PET search interest increased dramatically after March 2020, with sustained monthly growth (R²=0.87). By 2023, PSMA PET interest surpassed bone scan levels and approached MRI interest. FDA approval of Gallium-68 PSMA-11 generated the strongest public response, while guideline updates showed minimal immediate impact. Overall average interest rankings were: Prostate Cancer Scan (44.9), MRI Prostate Cancer (40.8), PSMA PET Scan (20.6), and Bone Scan Prostate Cancer (13.7).Conclusion: PSMA PET has rapidly captured public interest parallel to its clinical validation and regulatory approval, reflecting growing importance in prostate cancer imaging. Infodemiology approaches provide valuable insights into medical innovation ad3option and assist stakeholders in anticipating trends and developing health policies in molecular imaging.
- 23 January 2025
- Published by Springer Nature in Annals of Hematology
- p. 1-5
A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient
Early T-precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a rare and aggressive subtype of T-cell leukemia with poor prognosis and resistance to standard treatments. We report a 21-year-old male with ETP-ALL/LBL who, after an initial complete remission with the HOELZER protocol, experienced early relapse and was refractory to subsequent FLEND and BFM protocols. Following disease progression and complications, he was treated with a combination of daratumumab, venetoclax, azacitidine, and dexamethasone. This regimen achieved complete remission after one cycle. This case highlights the potential of this combination therapy as an effective treatment for refractory ETP-ALL/LBL, suggesting further research is warranted to validate its efficacy and safety.
- 23 January 2025
- Published by Springer Nature in Annals of Hematology
- p. 1-5
A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient
Early T-precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a rare and aggressive subtype of T-cell leukemia with poor prognosis and resistance to standard treatments. We report a 21-year-old male with ETP-ALL/LBL who, after an initial complete remission with the HOELZER protocol, experienced early relapse and was refractory to subsequent FLEND and BFM protocols. Following disease progression and complications, he was treated with a combination of daratumumab, venetoclax, azacitidine, and dexamethasone. This regimen achieved complete remission after one cycle. This case highlights the potential of this combination therapy as an effective treatment for refractory ETP-ALL/LBL, suggesting further research is warranted to validate its efficacy and safety.
- Open Access
- 31 December 2022
- Published by Acta Medica Alanya in Acta Medica Alanya
- Vol. 6 (3) , 301-306
Different metabolic and clinical profiles between patients with pure Alzheimer dementia and epileptic Alzheimer dementia: a metabolic study
Aim: To investigate the clinical characteristics and cerebral FDG PET metabolisms of dementia patients who were also diagnosed with epilepsy and compare the differences with pure Alzheimer dementia patients.Methods: In this case-control study, a total of 14 patients, 7 patients with pure Alzheimer disease as a control group and 7 age and gender-matched patients with Alzheimer disease and concomitant epilepsy as a study group, were included. Detailed neurocognitive battery and brain fludeoxyglucose positron emission tomography (FDG PET-CT) were performed for all subjects.Results: In comparison of neurocognitive test scores, there was no significant difference between the study and control groups. However, geriatric depression scale scores were significantly lower in study group than the controls (p= 0.026). In cerebral FDG-PET CT profiles of subjects we detected significantly lower metabolism in left and right cerebellum, left lentiform nucleus, right thalamus and vermis in the study group (p=0.008, p=0.023, p=0.003, p=0.002, p=0.002, respectively). In the right parietotemporal cortex and right and left associative visual cortex, we found higher metabolism in the study group than controls (p=0.023, p=0.012, p=0.003, respectively).Conclusion: Epileptic patients with Alzheimer’s dementia may have distinct clinical and metabolic profiles, than pure Alzheimer’s disease patients. Even if there is no difference in the neurocognitive clinical scores of the patients, depression and related functional abnormalities may be a biomarker of epileptic AD.
- 31 December 2022
- Published by Acta Medica Alanya in Acta Medica Alanya
- Vol. 6 (3) , 301-306
Open AccessDifferent metabolic and clinical profiles between patients with pure Alzheimer dementia and epileptic Alzheimer dementia: a metabolic study
Aim: To investigate the clinical characteristics and cerebral FDG PET metabolisms of dementia patients who were also diagnosed with epilepsy and compare the differences with pure Alzheimer dementia patients.Methods: In this case-control study, a total of 14 patients, 7 patients with pure Alzheimer disease as a control group and 7 age and gender-matched patients with Alzheimer disease and concomitant epilepsy as a study group, were included. Detailed neurocognitive battery and brain fludeoxyglucose positron emission tomography (FDG PET-CT) were performed for all subjects.Results: In comparison of neurocognitive test scores, there was no significant difference between the study and control groups. However, geriatric depression scale scores were significantly lower in study group than the controls (p= 0.026). In cerebral FDG-PET CT profiles of subjects we detected significantly lower metabolism in left and right cerebellum, left lentiform nucleus, right thalamus and vermis in the study group (p=0.008, p=0.023, p=0.003, p=0.002, p=0.002, respectively). In the right parietotemporal cortex and right and left associative visual cortex, we found higher metabolism in the study group than controls (p=0.023, p=0.012, p=0.003, respectively).Conclusion: Epileptic patients with Alzheimer’s dementia may have distinct clinical and metabolic profiles, than pure Alzheimer’s disease patients. Even if there is no difference in the neurocognitive clinical scores of the patients, depression and related functional abnormalities may be a biomarker of epileptic AD.
- RetractedOpen Access
- 3 May 2022
- Published by S. Karger AG in Breast Care
- Vol. 17 (5) , 470-479
The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer
Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy for assessing the efficacy of NAC has not been established yet, but several studies have shown that 18F-FDG PET/CT is a potential imaging tool for assessing pCR. The aim of this study is to investigate the merits of 18F-FDG PET/CT imaging in predicting pCR in both axillary and breast tissue and to establish a threshold maximum standard uptake value (SUVmax) for predicting the response after completion of NAC. Methods: A total of 186 LABC patients, treated with an NAC regimen according to tumor subtype, were retrospectively analyzed in this study. All patients underwent 18F-FDG PET/CT imaging before and after completion of NAC. PET parameters were measured in the most FDG avid breast tissue and axillary lymph nodes. We analyzed the correlation between the tumor SUVmax of the PET/CT response and the pCR after surgery. DFS was also evaluated with respect to pCR. Results: Higher pCR rates were significantly associated with a higher tumor grade, an initial Ki-67 ≥20% (p = 0.03 and p = 0.003, respectively), a triple-negative subtype (32.9%), and a human epidermal growth factor receptor 2 (HER-2)-positive subtype (24.7%) (p < 0.001). There was a significant correlation between the pCR and a complete response in 18F-FDG PET/CT (p < 0.001). The overall sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 18F-FDG PET/CT to determine the pCR after NAC were 100%, 72.2%, 85%, 75.2%, and 100%, respectively. We demonstrated a 1.1 cutoff SUVmax for breast tumors after NAC (OR: 3.94, 95% CI: 1.14–5.05, p = 0.004), the 18F-FDG PET/CT response to NAC (OR: 0.50, 95% CI: 0.25–0.99, p = 0.003), and the molecular subtype of breast tumors (OR: 0.58, 95% CI: 0.38–0.88, p = 0.011). Conclusion: Our results confirm that 18F-FDG PET/CT is a useful method for predicting the NAC response in LABC.
- 3 May 2022
- Published by S. Karger AG in Breast Care
- Vol. 17 (5) , 470-479
RetractedOpen AccessThe Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer
Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy for assessing the efficacy of NAC has not been established yet, but several studies have shown that 18F-FDG PET/CT is a potential imaging tool for assessing pCR. The aim of this study is to investigate the merits of 18F-FDG PET/CT imaging in predicting pCR in both axillary and breast tissue and to establish a threshold maximum standard uptake value (SUVmax) for predicting the response after completion of NAC. Methods: A total of 186 LABC patients, treated with an NAC regimen according to tumor subtype, were retrospectively analyzed in this study. All patients underwent 18F-FDG PET/CT imaging before and after completion of NAC. PET parameters were measured in the most FDG avid breast tissue and axillary lymph nodes. We analyzed the correlation between the tumor SUVmax of the PET/CT response and the pCR after surgery. DFS was also evaluated with respect to pCR. Results: Higher pCR rates were significantly associated with a higher tumor grade, an initial Ki-67 ≥20% (p = 0.03 and p = 0.003, respectively), a triple-negative subtype (32.9%), and a human epidermal growth factor receptor 2 (HER-2)-positive subtype (24.7%) (p < 0.001). There was a significant correlation between the pCR and a complete response in 18F-FDG PET/CT (p < 0.001). The overall sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 18F-FDG PET/CT to determine the pCR after NAC were 100%, 72.2%, 85%, 75.2%, and 100%, respectively. We demonstrated a 1.1 cutoff SUVmax for breast tumors after NAC (OR: 3.94, 95% CI: 1.14–5.05, p = 0.004), the 18F-FDG PET/CT response to NAC (OR: 0.50, 95% CI: 0.25–0.99, p = 0.003), and the molecular subtype of breast tumors (OR: 0.58, 95% CI: 0.38–0.88, p = 0.011). Conclusion: Our results confirm that 18F-FDG PET/CT is a useful method for predicting the NAC response in LABC.
- 26 August 2020
- Published by Galenos Yayinevi in Nuclear Medicine Seminars
- Vol. 6 (2) , 243-255
Guideline for Dopaminergic Imaging in Parkinsonian Syndromes
- 26 August 2020
- Published by Galenos Yayinevi in Nuclear Medicine Seminars
- Vol. 6 (2) , 243-255
Guideline for Dopaminergic Imaging in Parkinsonian Syndromes
- Open Access
- 1 July 2016
- Published by Galenos Yayinevi in Nuclear Medicine Seminars
- Vol. 2 (2) , 79-89
F-18 Flourodeoxy Glucose Positron Emission Tomography/Computed Tomography Imaging in Infection and Inflammation
- 1 July 2016
- Published by Galenos Yayinevi in Nuclear Medicine Seminars
- Vol. 2 (2) , 79-89
Open AccessF-18 Flourodeoxy Glucose Positron Emission Tomography/Computed Tomography Imaging in Infection and Inflammation